Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.5bn2025-01-01 → 2025-06-30Cons.Revenue IFRS
Revenue¥46.7bn2024-01-01 → 2024-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Operating income−¥2.6bn2025-01-01 → 2025-06-30Cons.Operating profit loss IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Profit before tax−¥2.9bn2025-01-01 → 2025-06-30Cons.Profit loss before tax IFRS
Profit before tax¥20.9bn2024-01-01 → 2024-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥2.1bn2025-01-01 → 2025-06-30Cons.Profit loss IFRS
Net income¥15.0bn2024-01-01 → 2024-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Total assets¥78.5bnat 2025-06-30Cons.Assets IFRS
Total assets¥92.8bnat 2024-12-31Cons.Assets IFRS
Total assets¥95.9bnat 2024-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥24.9bnat 2025-06-30Cons.Liabilities IFRS
Total liabilities¥36.0bnat 2024-12-31Cons.Liabilities IFRS
Net assets / equity¥53.7bnat 2025-06-30Cons.Equity IFRS
Net assets / equity¥56.8bnat 2024-12-31Cons.Equity IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31vCons.Equity IFRS
Equity (owners)¥53.7bnat 2025-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥56.8bnat 2024-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.3bnat 2025-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥48.1bnat 2024-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31vCons.Cash and cash equivalents IFRS
Operating cash flow−¥11.0bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥23.8bn2024-01-01 → 2024-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.3bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥8.4bn2024-01-01 → 2024-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.5bn2025-01-01 → 2025-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥3.0bn2024-01-01 → 2024-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-16.42025-01-01 → 2025-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥115.852024-01-01 → 2024-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥-16.42025-01-01 → 2025-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥115.682024-01-01 → 2024-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio68.3%at 2025-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.2%at 2024-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-01-01 → 2025-06-30−¥453m
Reconciling Itemsreconcilingrevenue intersegment2025-01-01 → 2025-06-30−¥453m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥761m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2025-01-01 → 2025-06-30−¥3.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2025-01-01 → 2025-06-30¥8.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2025-01-01 → 2025-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2025-01-01 → 2025-06-30¥453m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2025-01-01 → 2025-06-30¥436m
—segment totalrevenue2025-01-01 → 2025-06-30¥9.0bn
—segment totalrevenue external2025-01-01 → 2025-06-30¥8.5bn
—segment totalrevenue intersegment2025-01-01 → 2025-06-30¥453m
—segment totalsegment profit2025-01-01 → 2025-06-30−¥2.6bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 582
ItemContextValueUnit
Purchase of intangible assets inv cf IFRSCurrentYTDDuration-82220000JPY
Other inv cf IFRSPrior1YTDDuration22345000JPY
Other inv cf IFRSCurrentYTDDuration4249000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration9956370000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-1287521000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-1320000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-1320000000JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-183766000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-198307000JPY
Payments for purchase of treasury shares fin cf IFRSPrior1YTDDuration-143000JPY
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration-960908000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSPrior1YTDDuration18750000JPY
Proceeds from issuance of share acquisition rights fin cf IFRSCurrentYTDDuration－JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-1485160000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-2479216000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration158319000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration-70404000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration5969618000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-14789711000JPY
Cash and cash equivalents IFRSPrior2YearInstant19507861000JPY
Cash and cash equivalents IFRSPrior1YearInstant48117933000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant25477479000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant33328222000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember28480960000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7652665000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember36133625000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration36133625000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember177534000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember177534000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-177534000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember28480960000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember7830199000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember36311160000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-177534000JPY
Revenue IFRSPrior1YTDDuration36133625000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember24740819000JPY
Segment profit loss IFRSPrior1YTDDuration_jpcrp040300-q2r_E27486-000RadiopharmaceuticalsBusinessReportableSegmentMember-46535000JPY
Segment profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember24694283000JPY
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Segment profit loss IFRSPrior1YTDDuration24694283000JPY
Business combination related expenses IFRSPrior1YTDDuration45000000JPY
Operating profit loss IFRSPrior1YTDDuration24649283000JPY
Finance income IFRSPrior1YTDDuration335214000JPY
Finance costs IFRSPrior1YTDDuration136342000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-105927000JPY
Profit loss before tax IFRSPrior1YTDDuration24742228000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q2r_E27486-000DrugDiscoveryAndDevelopmentBusinessReportableSegmentMember760735000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2025-01-01/2025-06-30pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass